Double radiation attack may slow tough gut tumors

NCT ID NCT07150546

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding focused external radiation (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and effective for people with large, inoperable neuroendocrine tumors of the digestive system. About 15 adults whose tumors have grown despite prior treatment will receive both therapies. The goal is to see if the combination can better control the disease than the drug alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Email: •••••@•••••

    Contact

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Email: •••••@•••••

    Contact